GlassScriptPhysician profile
Zulekha Hamid
NPI 1134214893
$5,362.94
in general payments reported to CMS, 2019-2025
32 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $99.35 · 2022: $737 · 2023: $1,176 · 2024: $1,080 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,672 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,672.48 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $593.43 | 2019-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $468.10 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $400.32 | 2019-2025 | |
| Kyowa Kirin, INC. | $388.80 | 2023-2025 | Crysvita |
| Lilly USA, LLC | $336.51 | 2019-2025 | Mounjaro, Jardiance, Baqsimi |
| Corcept Therapeutics | $285.76 | 2023-2025 | Korlym |
| Dexcom, INC. | $265.32 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $255.10 | 2022-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $240.26 | 2019-2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $237.46 | 2022-2025 | |
| Cequr Corporation | $198.07 | 2025 | Cequr Simplicity |
| Medtronic, INC. | $195.72 | 2025 | Simplera Sensor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.15 | 2022-2024 | Jardiance |
| Insulet Corporation | $175.07 | 2023-2025 | Omnipod, Omnipod |
| Novartis Pharmaceuticals Corporation | $148.84 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $135.19 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Xeris Pharmaceuticals, INC. | $129.37 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $110.71 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $102.64 | 2023-2025 | |
| Horizon Therapeutics Plc | $97.31 | 2022 | |
| Astellas Pharma US INC | $96.06 | 2023 | Veozah |
| Medtronic Minimed, INC. | $77.86 | 2019 | |
| Nevro Corp. | $57.79 | 2023-2024 | Senza |
| Sequel Med Tech, LLC | $36.98 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $23.31 | 2024 | |
| Ascendis Pharma Endocrinology INC | $22.62 | 2023 | |
| Ascensia Diabetes Care US INC. | $21.04 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $18.93 | 2025 | Imcivree |
| Chiesi USA, INC. | $18.41 | 2025 | Mycapssa |
| Antares Pharma, INC. | $16.39 | 2024 | Xyosted |
| Globus Medical, INC. | $15.16 | 2025 | Senza |
| Amarin Pharma, INC. | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zulekha Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.